Terra Alpha Investments LLC Boosts Holdings in IQVIA Holdings Inc. $IQV

Terra Alpha Investments LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 25.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 9,616 shares of the medical research company’s stock after buying an additional 1,972 shares during the quarter. IQVIA makes up about 1.6% of Terra Alpha Investments LLC’s portfolio, making the stock its 26th largest position. Terra Alpha Investments LLC’s holdings in IQVIA were worth $1,515,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares in the last quarter. American Century Companies Inc. increased its stake in shares of IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of IQVIA by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Truist Financial upped their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Price Performance

Shares of IQVIA stock opened at $218.96 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $231.34. The stock has a market capitalization of $37.22 billion, a price-to-earnings ratio of 31.69, a price-to-earnings-growth ratio of 2.33 and a beta of 1.32. The company has a fifty day moving average of $192.71 and a 200-day moving average of $169.95. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the prior year, the company earned $2.64 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.